These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24060239)

  • 1. Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases.
    Jurecka A; Malinova V; Tylki-Szymańska A
    Mol Genet Metab; 2014 Feb; 111(2):212-3. PubMed ID: 24060239
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy for the mucopolysaccharidoses.
    Valayannopoulos V; Wijburg FA
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Overview of enzyme replacement therapy in mucopolysaccharidosis].
    Fouilhoux A; Guffon N
    Presse Med; 2007 Mar; 36 Spec No 1():1S96-9. PubMed ID: 17546776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI.
    Kör D; Şeker Yilmaz B; Bulut FD; Önenli Mungan N; Ufuk Altıntaş D
    J Investig Allergol Clin Immunol; 2016; 26(2):130-2. PubMed ID: 27164636
    [No Abstract]   [Full Text] [Related]  

  • 6. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
    Harmatz P
    Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.
    Krishnagiri C; Ajanahalli RR; Kashyap S; Anegundi R; Boranaik L
    Ann Diagn Pathol; 2013 Feb; 17(1):137-9. PubMed ID: 22056033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
    Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
    Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aryplase (Biomarin).
    Yogalingam G
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1111-20. PubMed ID: 15535433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): experience in Hong Kong.
    But WM; Wong MY; Chow JC; Chan WK; Ko WT; Wu SP; Wong ML; Miu TY; Tse WY; Hung WW; Fan TW; Shek CC
    Hong Kong Med J; 2011 Aug; 17(4):317-24. PubMed ID: 21813902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    Harmatz P; Whitley CB; Waber L; Pais R; Steiner R; Plecko B; Kaplan P; Simon J; Butensky E; Hopwood JJ
    J Pediatr; 2004 May; 144(5):574-80. PubMed ID: 15126989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study.
    Harmatz P; Kramer WG; Hopwood JJ; Simon J; Butensky E; Swiedler SJ;
    Acta Paediatr Suppl; 2005 Mar; 94(447):61-8; discussion 57. PubMed ID: 15895715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for the management of the mucopolysaccharidoses.
    Wraith JE
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S63-5. PubMed ID: 20040314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of early replacement therapy for mucopolysaccharidosis type VI: echocardiographic follow-up of siblings.
    Leal GN; de Paula AC; Morhy SS; Andrade JL; Kim CA
    Cardiol Young; 2014 Apr; 24(2):229-35. PubMed ID: 23458163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
    Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
    Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
    Harmatz P; Giugliani R; Schwartz I; Guffon N; Teles EL; Miranda MC; Wraith JE; Beck M; Arash L; Scarpa M; Yu ZF; Wittes J; Berger KI; Newman MS; Lowe AM; Kakkis E; Swiedler SJ;
    J Pediatr; 2006 Apr; 148(4):533-539. PubMed ID: 16647419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation.
    Whitley CB; Utz JR
    Mol Genet Metab; 2010 Dec; 101(4):346-8. PubMed ID: 20800524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
    Turner CT; Hopwood JJ; Bond CS; Brooks DA
    Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.